Trinity Biotech (TRIB) AI Stock Analysis

• Market Cap: $18.05M
• Dividend Yield: N/A
• Average Volume (3M): 136.14K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.62
• Revenue Growth: -4.40%
• EPS Growth: -6.31%
• Country: US
• Employees: 380
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): N/A
• Shares Outstanding: 18,632,019
• 10 Day Avg. Volume: 159,092
• 30 Day Avg. Volume: 136,139
• PEG Ratio: 0.06
• Price to Book (P/B): -2.25
• Price to Sales (P/S): 1.28
• P/FCF Ratio: -5.54
• Enterprise Value/Market Cap: 5.67
• Enterprise Value/Revenue: 1.88
• Enterprise Value/Gross Profit: 5.85
• Enterprise Value/Ebitda: -5.00
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Underperform
• Price Target: $1.00 ▲(6.38% Upside)

Trinity Biotech's overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues, high debt levels, and negative equity. Technical analysis provides some neutral signals, but the bearish trend remains a concern. The negative P/E ratio and lack of dividend yield further underscore the stock's unattractive valuation. Strategic interventions are needed to address financial instability and restore investor confidence.

Trinity Biotech Business Overview & Revenue Model

Company Description

Trinity Biotech is a biotechnology company that specializes in the development, manufacture, and marketing of diagnostic products for the healthcare sector. Operating primarily in the fields of infectious diseases, autoimmune diseases, and diabetes, Trinity Biotech offers a wide range of diagnostic testing solutions, including both rapid tests and laboratory-based assays. The company's core products include enzyme-linked immunosorbent assays (ELISA), point-of-care tests, and other diagnostic kits designed for use in hospitals, laboratories, and clinics worldwide.

How the Company Makes Money

Trinity Biotech generates revenue primarily through the sale of its diagnostic products to healthcare providers, laboratories, and distributors. The company's key revenue streams include the sale of immunodiagnostic tests, which are used to detect various diseases and conditions, and point-of-care testing devices that provide rapid results. Additionally, Trinity Biotech's revenue is bolstered by strategic partnerships and collaborations with other healthcare companies, which help expand its market reach and enhance its product offerings. The company also benefits from ongoing demand for its diabetes and infectious disease testing products, driving consistent sales growth in a competitive market.

Trinity Biotech Financial Statement Overview

Summary

Trinity Biotech is experiencing significant financial challenges, with declining revenues and profitability, high debt levels, and negative equity. The company faces risks related to financial stability and sustainability. While there are some improvements in operating cash flows, overall financial health is weak, requiring strategic interventions to restore growth and stability.

Income Statement

Trinity Biotech has been experiencing declining revenues and profitability in recent years. The gross profit margin has decreased, and the company has been running at a net loss, with net profit margins consistently negative. The revenue growth rate is negative, indicating shrinking sales year-over-year. Both EBIT and EBITDA margins have also been negative, reflecting operational inefficiencies and challenges in covering operational costs.

Balance Sheet

The balance sheet shows significant financial distress, with negative stockholders' equity indicating more liabilities than assets. The debt-to-equity ratio is not calculable due to negative equity, but high total debt levels are concerning. The equity ratio is negative, highlighting an unsustainable financial structure. Return on equity is negative as well, reflecting ongoing losses.

Cash Flow

Cash flow metrics indicate challenges but also some operational cash inflow improvements in the latest year. Free cash flow remains negative, though the operating cash flow to net income ratio suggests some improvement in cash generation relative to net losses. However, consistent negative free cash flow indicates cash management issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	54.43M	61.55M	56.83M	62.52M	81.15M	101.98M
Gross Profit	17.49M	21.44M	19.45M	22.05M	33.45M	48.58M
EBITDA	-20.46M	-16.91M	-24.10M	-16.71M	10.59M	3.19M
Net Income	-37.28M	-31.79M	-24.02M	-41.00M	875.00K	-6.39M
Balance Sheet
Total Assets	99.79M	103.29M	59.44M	92.10M	118.89M	130.40M
Cash, Cash Equivalents and Short-Term Investments	4.07M	5.17M	3.69M	6.58M	25.91M	27.33M
Total Debt	107.97M	100.76M	67.43M	72.20M	99.16M	104.34M
Total Liabilities	143.41M	138.47M	83.38M	94.28M	119.21M	132.62M
Stockholders Equity	-43.63M	-35.18M	-23.95M	-2.18M	-319.00K	-2.22M
Cash Flow
Free Cash Flow	-12.99M	-14.26M	-12.36M	-6.90M	4.55M	13.56M
Operating Cash Flow	-4.34M	-4.19M	-11.56M	-921.00K	13.24M	23.75M
Investing Cash Flow	-10.99M	-22.97M	24.76M	-5.98M	-8.69M	-10.20M
Financing Cash Flow	13.78M	28.81M	-16.04M	-12.32M	-6.02M	-2.72M

Trinity Biotech Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.94
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRIB, the sentiment is Negative. The current price of 0.94 is below the 20-day moving average (MA) of 0.99, below the 50-day MA of 1.08, and above the 200-day MA of 0.86, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 40.13 is Neutral, neither overbought nor oversold. The STOCH value of 24.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TRIB.

Trinity Biotech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRPO	55 Neutral	$32.51M	-16.60	-14.76%	―	27.05%	55.03%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BNGO	41 Neutral	$16.58M	-0.04	-118.26%	―	-25.02%	85.08%
TRIB	40 Underperform	$18.05M	-0.34	―	―	-4.40%	-6.31%
INBS	39 Underperform	$7.00M	―	-186.64%	―	-1.90%	87.72%
BIAF	38 Underperform	$9.40M	-0.10	-1802.45%	―	4.99%	22.58%
CHEK	26 Underperform	$9.13M	―	―	―	―	―

Trinity Biotech Corporate Events

Trinity Biotech Amends Constitution and Credit Agreement Following AGM

At the Annual General Meeting on September 30, 2025, Trinity Biotech’s shareholders approved amendments to the company’s Constitution, which were subsequently disclosed. Additionally, the company and its subsidiaries amended their credit agreement with Perceptive Credit Holdings III, L.P., reflecting a strategic financial adjustment. These changes are indicative of Trinity Biotech’s efforts to refine its corporate governance and financial strategies, potentially impacting its operational flexibility and stakeholder relations.

Trinity Biotech Announces AGM Results and Board Changes

On September 30, 2025, Trinity Biotech plc held its annual general meeting where shareholders approved all proposed resolutions with at least 93% of votes. Key resolutions included the re-appointment of Grant Thornton as statutory auditor, authorization for the board to fix auditors’ remuneration, reduction of nominal value of A Ordinary Shares, increase in authorized share capital, and refreshing the board’s authority to issue new shares. Jim Walsh retired from the board but will continue as a Scientific Advisor, highlighting his long-term commitment to the company.

Trinity Biotech Releases 2024 Annual Report

Trinity Biotech has released its Annual Report for 2024, which includes key documents such as the Company Secretary’s letter, Notice of Annual General Meeting, and AGM Proxy Card. The report, dated September 8, 2025, provides insights into the company’s financial performance, strategic direction, and management structure, highlighting the leadership of CEO John Gillard. This announcement is significant for stakeholders as it outlines the company’s operational and financial status, potentially impacting its market position and investor confidence.

Trinity Biotech Regains Nasdaq Compliance as of September 2025

On September 2, 2025, Trinity Biotech announced it regained compliance with Nasdaq’s listing requirements, specifically the $1.00 minimum bid price and the minimum market value of publicly held shares. This follows a period of non-compliance noted on March 14, 2025, and subsequent improvements in share price and market value by August 2025. The resolution of these compliance issues is significant for Trinity Biotech’s continued listing on the Nasdaq, which is crucial for maintaining investor confidence and market presence.

Trinity Biotech Receives Approval for Offshore Manufacturing of HIV Test

On August 20, 2025, Trinity Biotech announced it received regulatory approval to commence offshore and outsourced manufacturing of its flagship TrinScreen™ HIV rapid test. This strategic move is expected to enhance the company’s financial performance by expanding gross margins, freeing up working capital, and reducing fixed costs, thereby supporting broader profitability and growth objectives. The transition to a more cost-effective and scalable production model marks a critical milestone in Trinity Biotech’s transformation strategy, positioning the company for long-term financial health and improved industry positioning.

Trinity Biotech Gains Approval for PreClara™ Preeclampsia Testing Service

On August 14, 2025, Trinity Biotech announced that it received regulatory approval from the New York State Department of Health to begin offering its FDA-cleared PreClara™ preeclampsia testing service. This approval is a significant milestone in the company’s maternal health strategy, enhancing its position in the U.S. diagnostics market. The PreClara™ test provides crucial insights for managing hypertensive disorders in pregnancy, potentially reducing neonatal costs by over $10 million per 1,000 patients. This development also supports the future introduction of Trinity Biotech’s PrePsia™ technology for early pregnancy risk assessment.

Trinity Biotech Announces Breakthrough in CGM Technology

On August 12, 2025, Trinity Biotech announced breakthrough clinical trial results for its redesigned continuous glucose monitoring (CGM) sensor, marking a significant milestone in diabetes management technology. The trial confirmed that the new needle-free glucose sensor provides accurate readings over a 15-day period without finger-stick calibration, enhancing user convenience and reducing costs. This advancement positions Trinity Biotech to expand access to CGM technology in a growing market, projected to reach $28 billion by 2030, by offering a more affordable and sustainable product.

Trinity Biotech Launches FDA-cleared Preeclampsia Testing Service

On August 7, 2025, Trinity Biotech announced the launch of its FDA-cleared PreClara™ Ratio (sFlt-1/PlGF) biomarker test, a significant advancement in maternal health diagnostics. This new testing service, developed in collaboration with Thermo Fisher Scientific, will be available through Trinity Biotech’s New York-based reference laboratory in Q3 2025. The test is designed to provide clinicians with critical insights for managing hypertensive disorders of pregnancy, potentially leading to significant cost savings and improved patient outcomes. This strategic milestone enhances Trinity Biotech’s position in the maternal health sector and reflects its commitment to addressing urgent healthcare needs.